Sunday, May 14, 2023 10:00 AM – 10:45 AM ET Exhibit Hall D, Room 2
Exhibitor Workshop: Sartorius
Comparing Tumor Killing Mechanisms of Antibody Drug Conjugates (ADC’s) with the iQue® Flow Cytometry System
- Kirsty McBain, Scientist
- Don Weldon, Cell Analysis Technology Expert, Product Management
Antibody drug conjugates (ADCs) marry together two types of cancer treatment, chemotherapy and immunotherapy, to create highly-specific and efficacious therapeutics. Each ADC has been designed with unique features such as the position, number and identity of the cytotoxic payload, as well as the structure of the adjoining linker. These characteristics mean that even ADCs based on the same monoclonal antibody backbone can have largely different functional profiles. We describe the use of the iQue® Flow Cytometry Platform to profile the binding and tumor cell- killing mechanism of anti-HER2 ADCs.